Long-term safety and efficacy of deferasirox in patients with myelodysplastic syndrome, aplastic anemia and other rare anemia in Taiwan

Bor Sheng Ko, Ming Chih Chang, Tzeon Jye Chiou, Te Kau Chang, Yeu Chin Chen, Sheng Fung Lin, Cheng Shyong Chang, Yin Che Lu, Su Peng Yeh, Tsai Yun Chen, Wei Shou Hwang

研究成果: Article

摘要

Objective: Patients with myelodysplastic syndromes (MDS), aplastic anemia (AA) or other rare anemia require chronic blood transfusions which can lead to iron overload and subsequent excess iron-mediated complications. Intensive iron chelation with deferasirox could remove excess iron and can alleviate these events; however, the long-term safety and efficacy in Chinese population are not clearly characterized. This study examined the long-term efficacy and safety of deferasirox in a real-world setting in Taiwan. Methods: This observational, non-interventional, single-arm, multi-center, phase IV study was designed to collect the safety and clinical information about patients who were treated with deferasirox according to investigator’s judgment and in accordance with the general clinical practice. Results: From 2009 to 2011, patients with MDS (N = 38), AA (N = 23), and other rare anemias (N = 18) were enrolled. The mean deferasirox exposure was 17.7 ± 4.02 mg/kg/day. The most common drug-related AEs were skin disorders (32.9%) and gastrointestinal disorders (30.4%), while grade 3–4 AEs were rare (5.1%). In the overall patient population, deferasirox effectively decreased serum ferritin levels at 1 year (P = 0.0154) and 3 years (P = 0.0424) from the baseline. Upon the use of deferasirox, 32.9% patients showed erythroid response and 16.7% patients had platelet response. Conclusions: For patients with MDS, AA, and other rare anemias, the AEs observed in this 3-year surveillance study with deferasirox were mostly mild or moderate. In addition, the hematological response rate was higher than that in the EPIC study, which primarily enrolled Caucasian patients.

原文English
頁(從 - 到)247-254
頁數8
期刊Hematology (United Kingdom)
24
發行號1
DOIs
出版狀態Published - 2019 一月 1

指紋

Aplastic Anemia
Myelodysplastic Syndromes
Taiwan
Anemia
Safety
Iron
Iron Overload
deferasirox
Ferritins
Blood Transfusion
General Practice
Population
Blood Platelets
Research Personnel
Skin
Serum
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Hematology

引用此文

Ko, Bor Sheng ; Chang, Ming Chih ; Chiou, Tzeon Jye ; Chang, Te Kau ; Chen, Yeu Chin ; Lin, Sheng Fung ; Chang, Cheng Shyong ; Lu, Yin Che ; Yeh, Su Peng ; Chen, Tsai Yun ; Hwang, Wei Shou. / Long-term safety and efficacy of deferasirox in patients with myelodysplastic syndrome, aplastic anemia and other rare anemia in Taiwan. 於: Hematology (United Kingdom). 2019 ; 卷 24, 編號 1. 頁 247-254.
@article{802e8cd98bda4901b54eaff2d89c41fc,
title = "Long-term safety and efficacy of deferasirox in patients with myelodysplastic syndrome, aplastic anemia and other rare anemia in Taiwan",
abstract = "Objective: Patients with myelodysplastic syndromes (MDS), aplastic anemia (AA) or other rare anemia require chronic blood transfusions which can lead to iron overload and subsequent excess iron-mediated complications. Intensive iron chelation with deferasirox could remove excess iron and can alleviate these events; however, the long-term safety and efficacy in Chinese population are not clearly characterized. This study examined the long-term efficacy and safety of deferasirox in a real-world setting in Taiwan. Methods: This observational, non-interventional, single-arm, multi-center, phase IV study was designed to collect the safety and clinical information about patients who were treated with deferasirox according to investigator’s judgment and in accordance with the general clinical practice. Results: From 2009 to 2011, patients with MDS (N = 38), AA (N = 23), and other rare anemias (N = 18) were enrolled. The mean deferasirox exposure was 17.7 ± 4.02 mg/kg/day. The most common drug-related AEs were skin disorders (32.9{\%}) and gastrointestinal disorders (30.4{\%}), while grade 3–4 AEs were rare (5.1{\%}). In the overall patient population, deferasirox effectively decreased serum ferritin levels at 1 year (P = 0.0154) and 3 years (P = 0.0424) from the baseline. Upon the use of deferasirox, 32.9{\%} patients showed erythroid response and 16.7{\%} patients had platelet response. Conclusions: For patients with MDS, AA, and other rare anemias, the AEs observed in this 3-year surveillance study with deferasirox were mostly mild or moderate. In addition, the hematological response rate was higher than that in the EPIC study, which primarily enrolled Caucasian patients.",
author = "Ko, {Bor Sheng} and Chang, {Ming Chih} and Chiou, {Tzeon Jye} and Chang, {Te Kau} and Chen, {Yeu Chin} and Lin, {Sheng Fung} and Chang, {Cheng Shyong} and Lu, {Yin Che} and Yeh, {Su Peng} and Chen, {Tsai Yun} and Hwang, {Wei Shou}",
year = "2019",
month = "1",
day = "1",
doi = "10.1080/16078454.2018.1557860",
language = "English",
volume = "24",
pages = "247--254",
journal = "Hematology",
issn = "1024-5332",
publisher = "Taylor and Francis Ltd.",
number = "1",

}

Long-term safety and efficacy of deferasirox in patients with myelodysplastic syndrome, aplastic anemia and other rare anemia in Taiwan. / Ko, Bor Sheng; Chang, Ming Chih; Chiou, Tzeon Jye; Chang, Te Kau; Chen, Yeu Chin; Lin, Sheng Fung; Chang, Cheng Shyong; Lu, Yin Che; Yeh, Su Peng; Chen, Tsai Yun; Hwang, Wei Shou.

於: Hematology (United Kingdom), 卷 24, 編號 1, 01.01.2019, p. 247-254.

研究成果: Article

TY - JOUR

T1 - Long-term safety and efficacy of deferasirox in patients with myelodysplastic syndrome, aplastic anemia and other rare anemia in Taiwan

AU - Ko, Bor Sheng

AU - Chang, Ming Chih

AU - Chiou, Tzeon Jye

AU - Chang, Te Kau

AU - Chen, Yeu Chin

AU - Lin, Sheng Fung

AU - Chang, Cheng Shyong

AU - Lu, Yin Che

AU - Yeh, Su Peng

AU - Chen, Tsai Yun

AU - Hwang, Wei Shou

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objective: Patients with myelodysplastic syndromes (MDS), aplastic anemia (AA) or other rare anemia require chronic blood transfusions which can lead to iron overload and subsequent excess iron-mediated complications. Intensive iron chelation with deferasirox could remove excess iron and can alleviate these events; however, the long-term safety and efficacy in Chinese population are not clearly characterized. This study examined the long-term efficacy and safety of deferasirox in a real-world setting in Taiwan. Methods: This observational, non-interventional, single-arm, multi-center, phase IV study was designed to collect the safety and clinical information about patients who were treated with deferasirox according to investigator’s judgment and in accordance with the general clinical practice. Results: From 2009 to 2011, patients with MDS (N = 38), AA (N = 23), and other rare anemias (N = 18) were enrolled. The mean deferasirox exposure was 17.7 ± 4.02 mg/kg/day. The most common drug-related AEs were skin disorders (32.9%) and gastrointestinal disorders (30.4%), while grade 3–4 AEs were rare (5.1%). In the overall patient population, deferasirox effectively decreased serum ferritin levels at 1 year (P = 0.0154) and 3 years (P = 0.0424) from the baseline. Upon the use of deferasirox, 32.9% patients showed erythroid response and 16.7% patients had platelet response. Conclusions: For patients with MDS, AA, and other rare anemias, the AEs observed in this 3-year surveillance study with deferasirox were mostly mild or moderate. In addition, the hematological response rate was higher than that in the EPIC study, which primarily enrolled Caucasian patients.

AB - Objective: Patients with myelodysplastic syndromes (MDS), aplastic anemia (AA) or other rare anemia require chronic blood transfusions which can lead to iron overload and subsequent excess iron-mediated complications. Intensive iron chelation with deferasirox could remove excess iron and can alleviate these events; however, the long-term safety and efficacy in Chinese population are not clearly characterized. This study examined the long-term efficacy and safety of deferasirox in a real-world setting in Taiwan. Methods: This observational, non-interventional, single-arm, multi-center, phase IV study was designed to collect the safety and clinical information about patients who were treated with deferasirox according to investigator’s judgment and in accordance with the general clinical practice. Results: From 2009 to 2011, patients with MDS (N = 38), AA (N = 23), and other rare anemias (N = 18) were enrolled. The mean deferasirox exposure was 17.7 ± 4.02 mg/kg/day. The most common drug-related AEs were skin disorders (32.9%) and gastrointestinal disorders (30.4%), while grade 3–4 AEs were rare (5.1%). In the overall patient population, deferasirox effectively decreased serum ferritin levels at 1 year (P = 0.0154) and 3 years (P = 0.0424) from the baseline. Upon the use of deferasirox, 32.9% patients showed erythroid response and 16.7% patients had platelet response. Conclusions: For patients with MDS, AA, and other rare anemias, the AEs observed in this 3-year surveillance study with deferasirox were mostly mild or moderate. In addition, the hematological response rate was higher than that in the EPIC study, which primarily enrolled Caucasian patients.

UR - http://www.scopus.com/inward/record.url?scp=85058734002&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058734002&partnerID=8YFLogxK

U2 - 10.1080/16078454.2018.1557860

DO - 10.1080/16078454.2018.1557860

M3 - Article

C2 - 30558522

AN - SCOPUS:85058734002

VL - 24

SP - 247

EP - 254

JO - Hematology

JF - Hematology

SN - 1024-5332

IS - 1

ER -